| Engineered immunogen binding to alum adjuvant enhances humoral immunity TJ Moyer, Y Kato, W Abraham, JYH Chang, DW Kulp, N Watson, ... Nature Medicine 26 (3), 430-440, 2020 | 235 | 2020 |
| Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity Y Agarwal, LE Milling, JYH Chang, L Santollani, A Sheen, EA Lutz, ... Nature biomedical engineering 6 (2), 129-143, 2022 | 106 | 2022 |
| High-performance chemical-and light-inducible recombinases in mammalian cells and mice BH Weinberg, JH Cho, Y Agarwal, NTH Pham, LD Caraballo, M Walkosz, ... Nature communications 10 (1), 4845, 2019 | 67 | 2019 |
| Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains KS Gordon, T Kyung, CR Perez, PV Holec, A Ramos, AQ Zhang, ... Nature biomedical engineering 6 (7), 855-866, 2022 | 42 | 2022 |
| Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade C Wang, A Cui, M Bukenya, A Aung, D Pradhan, CA Whittaker, Y Agarwal, ... Cell reports 37 (8), 2021 | 31 | 2021 |
| Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies EA Lutz, Y Agarwal, N Momin, SC Cowles, JR Palmeri, E Duong, V Hornet, ... Proceedings of the National Academy of Sciences 119 (36), e2205983119, 2022 | 26 | 2022 |
| Neoadjuvant STING activation, extended half-life IL2, and checkpoint blockade promote metastasis clearance via sustained NK-cell activation LE Milling, D Garafola, Y Agarwal, S Wu, A Thomas, N Donahue, J Adams, ... Cancer immunology research 10 (1), 26-39, 2022 | 16 | 2022 |
| Tumor-localized catalases can fail to alter tumor growth and transcriptional profiles in subcutaneous syngeneic mouse tumor models A Sheen, Y Agarwal, KM Cheah, SC Cowles, JA Stinson, JR Palmeri, ... Redox Biology 64, 102766, 2023 | 10 | 2023 |
| Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2 BL Horton, A D D’Souza, M Zagorulya, CV McCreery, GC Abhiraman, ... JCI insight 8 (19), e172728, 2023 | 9 | 2023 |
| Co‐anchoring of engineered immunogen and immunostimulatory cytokines to alum promotes enhanced‐humoral immunity JYH Chang, Y Agarwal, KA Rodrigues, N Momin, K Ni, BJ Read, TJ Moyer, ... Advanced Therapeutics 5 (7), 2100235, 2022 | 7 | 2022 |
| Author Correction: A Engineered immunogen binding to alum adjuvant enhances humoral immunity TJ Moyer, Y Kato, W Abraham, JYH Chang, DW Kulp, N Watson, ... Nature Medicine 26 (5), 804-804, 2020 | 7 | 2020 |
| Optimization of an alum-anchored clinical HIV vaccine candidate KA Rodrigues, CA Cottrell, JM Steichen, B Groschel, W Abraham, H Suh, ... npj Vaccines 8 (1), 117, 2023 | 6 | 2023 |
| 1087 Addition of IL-2 overcomes lung tumor resistance to IL-12 by coordinating cytotoxic and regulatory T cell responses B Horton, M Zagorulya, N Momin, Y Agarwal, K Wittrup, S Spranger J Immunother Cancer 10 (Suppl 2), A1-A1603, 2022 | 3 | 2022 |
| Reprogramming brain immunosurveillance with engineered cytokines A Tabet, Y Agarwal, J Stinson, C Apra, V Will, M Manthey, N Momin, ... bioRxiv, 2022.06. 21.497082, 2022 | 1 | 2022 |
| A materials-based approach for localized delivery of cancer immunotherapy Y Agarwal Massachusetts Institute of Technology, 2022 | | 2022 |
| 738 Intratumoral administration of alum-tethered engineered inflammatory cytokines safely elicits potent local and systemic immunity Y Agarwal, K Wittrup, D Irvine Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | | 2021 |